“Promomed” is currently evaluating the efficacy of a new medication in the fight against both COVID-19 and influenza. In early November, the Russian company received approval from the Ministry of Health to commence its clinical trials, as officially recorded in the State Register of Medicines. The trial protocol, identified as MOL-042024, specifies the test drug is formulated in 200 mg capsules. Molnupiravir is currently produced in the same form and dosage, including by Promomed – under the brand name “Esperavir”.
A total of 430 patients across ten medical institutions are participating in clinical trials assessing the efficacy of a treatment compared to a placebo. This groundbreaking experiment is set to continue until December 2025. Demand for molnupiravir drugs around the world has fallen sharply along with the incidence of COVID-19.